Rallybio Corp (RLYB) Financial Statements (2026 and earlier)

Company Profile

Business Address 234 CHURCH STREET
NEW HAVEN, CT 06510
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)
Annual | Quarterly

3/31/2026
MRQ
12/31/2025
12/31/2024
12/31/2023
12/31/2022
12/31/2021
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:54,70065,500109,900169,000175,334
Cash and cash equivalent31,37413,90324,49456,958175,334
Short-term investments23,36251,60885,435112,036 
Other undisclosed cash, cash equivalents, and short-term investments(36)(11)(29)6 
Receivables     
Prepaid expense6286387391,548 
Deferred costs    100 
Other current assets2,5179952,0541,050 
Other undisclosed current assets3,4087082,0967,7985,535
Total current assets:61,25367,841114,789179,496180,869
Noncurrent Assets
Operating lease, right-of-use asset175152346524 
Property, plant, and equipment, after accumulated depreciation, depletion, and amortization23115246385511
Long-term investments and receivables   23930805
Long-term investments   23930805
Other noncurrent assets810    
Total noncurrent assets:1,0082678319391,316
TOTAL ASSETS:62,26168,108115,620180,435182,185
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities3,9175,2409,04410,5636,551
Accounts payable1262789761,114603
Accrued liabilities3,7914,9628,0689,4495,948
Deferred revenue 212848   
Other undisclosed current liabilities94154219181 
Total current liabilities:4,2236,2429,26310,7446,551
Noncurrent Liabilities
Liabilities, other than long-term debt8221217337432
Accounts payable and accrued liabilities     32
Deferred revenue  212   
Operating lease, liability82 173374 
Total noncurrent liabilities:8221217337432
Total liabilities:4,3056,4549,43611,1186,583
Equity
Equity, attributable to parent57,95661,654106,184169,317175,602
Common stock44443
Additional paid in capital359,932354,602341,410330,208269,626
Accumulated other comprehensive income (loss)186815(214) 
Accumulated deficit(301,998)(293,020)(235,245)(160,681)(94,027)
Total equity:57,95661,654106,184169,317175,602
TOTAL LIABILITIES AND EQUITY:62,26168,108115,620180,435182,185

Income Statement (P&L) ($ in thousands)
Annual | Quarterly

3/31/2026
TTM
12/31/2025
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Revenues858600   
Gross profit:858600   
Operating expenses(33,922)(61,132)(78,932)(67,884)(45,648)
Other undisclosed operating income  36   
Operating loss:(33,064)(60,496)(78,932)(67,884)(45,648)
Nonoperating income24,9604,9606,4092,305140
Other nonoperating income22,77174426234296
Interest and debt expense     (10)
Loss from continuing operations before equity method investments, income taxes:(8,104)(55,536)(72,523)(65,579)(45,518)
Loss from equity method investments(874)(2,239)(2,041)  
Other undisclosed income from continuing operations before income taxes     10
Loss from continuing operations:(8,978)(57,775)(74,564)(65,579)(45,508)
Loss before gain (loss) on sale of properties:✕✕✕✕✕(45,508)
Other undisclosed net loss     (1,505)
Net loss:(8,978)(57,775)(74,564)(65,579)(47,013)
Other undisclosed net loss attributable to parent    (1,075) 
Net loss available to common stockholders, diluted:(8,978)(57,775)(74,564)(66,654)(47,013)

Comprehensive Income ($ in thousands)
Annual | Quarterly

3/31/2026
TTM
12/31/2025
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Net loss:(8,978)(57,775)(74,564)(65,579)(47,013)
Other comprehensive income (loss)(50)53229(214) 
Comprehensive loss:(9,028)(57,722)(74,335)(65,793)(47,013)
Other undisclosed comprehensive loss, net of tax, attributable to parent    (1,075) 
Comprehensive loss, net of tax, attributable to parent:(9,028)(57,722)(74,335)(66,868)(47,013)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: